ProfileGDS5678 / 1431321_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 39% 43% 43% 43% 46% 49% 44% 43% 41% 43% 40% 43% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0116942
GSM967853U87-EV human glioblastoma xenograft - Control 22.9014839
GSM967854U87-EV human glioblastoma xenograft - Control 32.9968943
GSM967855U87-EV human glioblastoma xenograft - Control 42.9438143
GSM967856U87-EV human glioblastoma xenograft - Control 52.936943
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1659846
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.260149
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0066344
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9615543
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9200241
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9811243
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8927840
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9903243
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1670649